MedPath

PFIZER INC.

PFIZER INC. logo
🇺🇸United States
Ownership
Public
Established
1849-01-01
Employees
88K
Market Cap
$163.3B
Website
http://www.pfizer.com
Clinical Trials
Related News

A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

Phase 2
Withdrawn
Conditions
Breast Neoplasms
First Posted Date
2007-05-09
Last Posted Date
2015-05-04
Lead Sponsor
Pfizer
Registration Number
NCT00471159

A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.

Phase 2
Completed
Conditions
Asthma
First Posted Date
2007-05-03
Last Posted Date
2010-11-01
Lead Sponsor
Pfizer
Target Recruit Count
42
Registration Number
NCT00468975
Locations
🇬🇧

Pfizer Investigational Site, Manchester, United Kingdom

Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease

Not Applicable
Completed
Conditions
Alzheimer Disease
Caregivers
First Posted Date
2007-05-01
Last Posted Date
2007-05-07
Lead Sponsor
Pfizer
Target Recruit Count
300
Registration Number
NCT00467766
Locations
🇺🇸

Aging and Dementia Research Center, Silberstein Institute, NYU School of Medicine, New York, New York, United States

🇦🇺

Prince of Wales Hospital, Randwick, New South Wales, Australia

🇬🇧

University of Manchester, Division of Psychiatry, Manchester, United Kingdom

Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.

Withdrawn
Conditions
Abscess, Intra-Abdominal
Cholecystitis
Wound Infections
Peritonitis
Appendicitis
First Posted Date
2007-04-20
Last Posted Date
2011-04-22
Lead Sponsor
Pfizer
Registration Number
NCT00463762

A Phase I Study to Evaluate the Pharmacokinetics of Multiple Doses of Varenicline in Healthy Adolescent Smokers

Phase 1
Completed
Conditions
Smoking Cessation
First Posted Date
2007-04-20
Last Posted Date
2008-11-19
Lead Sponsor
Pfizer
Target Recruit Count
73
Registration Number
NCT00463918
Locations
🇬🇧

Pfizer Investigational Site, Slough, Berkshire, United Kingdom

Study Investigating the Safety and Tolerability of Multiple Doses of PF-02545920 in Subjects With Schizophrenia

Phase 1
Completed
Conditions
Schizophrenia
Schizo-affective Disorder
First Posted Date
2007-04-20
Last Posted Date
2018-09-05
Lead Sponsor
Pfizer
Target Recruit Count
40
Registration Number
NCT00463372
Locations
🇿🇦

Pfizer Investigational Site, George, South Africa

Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer

Phase 1
Completed
Conditions
Colorectal Neoplasms
Interventions
Drug: AG-013726
Drug: AG-013736 (axitinib)
Drug: bevacizumab
First Posted Date
2007-04-16
Last Posted Date
2013-12-06
Lead Sponsor
Pfizer
Target Recruit Count
187
Registration Number
NCT00460603
Locations
🇺🇸

Pfizer Investigational Site, Vancouver, Washington, United States

SUTENT® In The First Line Treatment Of Renal Cell Carcinoma

Completed
Conditions
Renal Cell Carcinoma
First Posted Date
2007-04-16
Last Posted Date
2010-11-16
Lead Sponsor
Pfizer
Target Recruit Count
356
Registration Number
NCT00460798

Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule

Phase 3
Completed
Conditions
Encephalitis, Tick-Borne
First Posted Date
2007-04-16
Last Posted Date
2023-04-19
Lead Sponsor
Pfizer
Target Recruit Count
330
Registration Number
NCT00460486
Locations
🇵🇱

Niepubliczny ZOZ "VITA", Olsztyn, Poland

🇵🇱

Centrum Badan Farmakologii Klinicznej monipol, Krakow, Poland

🇵🇱

Niepubliczny ZOZ "Atarax" s.c., Olsztyn, Poland

and more 1 locations

Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

Completed
Conditions
Macular Degeneration
Interventions
Drug: Macugen
First Posted Date
2007-04-16
Last Posted Date
2012-12-11
Lead Sponsor
Pfizer
Target Recruit Count
501
Registration Number
NCT00460408
Locations
🇸🇪

Pfizer Investigational Site, Västerås, Sweden

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy